Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • eye disease

    - PMLiVE

    bluebird bio lodges counterclaim against Spark Therapeutics

    Spark previously accused bluebird of misusing trademarks relating to the word ‘spark’ in marketing/educational materials

    Roche Basel Switzerland

    Roche to close $4.3bn Spark deal after FTC clearance

    Comes on the heels of CMA green light

    - PMLiVE

    Sangamo steps up BioMarin chase with haemophilia gene therapy data

    Updated results presented at ASH 2019

    Roche Basel Switzerland

    Roche moving closer to approval of Spark takeover; report

    Antitrust authorities in both US and UK look likely to end delay

    Roche Basel Switzerland

    Roche reports continued growth in Q3, despite biosimilar competition

    Spark acquisition expected to complete this year

    - PMLiVE

    NICE backs NHS use of Novartis’ gene therapy Luxturna

    First and only therapy for rare, inherited form of blindness

    - PMLiVE

    Roche reveals yet another Spark takeover delay

    Are concerns about haemophilia dominance the cause?

    - PMLiVE

    Roche buys gene therapy specialist Spark for $4.3bn

    Can compete with rival Novartis in fast-developing area

    - PMLiVE

    Novartis gets EU nod for Luxturna gene therapy

    Approval comes almost a year after it was secured a green light in the US

    - PMLiVE

    Spark sputters on haemophilia A gene therapy safety scare

    Investors compare data unfavourably with BioMarin rival

    - PMLiVE

    Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

    Big departure from repurposing - Spark's Fraser Wright comes on board

    - PMLiVE

    More encouraging data for Spark and Pfizer’s potential haemophilia B cure

    Pfizer set to commence phase III trials

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links